Tocagen Inc Contracts & Agreements

Registration Rights Agreement, dated November 19, 2024, by and among the Company and the Purchasers (Filed With SEC on November 20, 2024)

Form of Pre-Funded Warrant (Filed With SEC on November 20, 2024)

Securities Purchase Agreement, dated November 19, 2024, by and among the Company and the Purchasers (Filed With SEC on November 20, 2024)

Amended and Restated 2021 Equity Incentive Plan (Filed With SEC on August 22, 2024)

Standstill and Voting Agreement dated June 11, 2024, by and between the Company and the Camac Group (Filed With SEC on June 14, 2024)

Separation Agreement and Release by and between the Company and Hubert Chen, dated March 17, 2024 (Filed With SEC on May 13, 2024)

Amended and Restated 2021 Equity Incentive Plan, and forms of agreements thereunder (Filed With SEC on March 18, 2024)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 18, 2024)

Amended and Restated 2021 Equity Incentive Plan (Filed With SEC on September 20, 2023)

Form of Pre-Funded Warrant (Filed With SEC on August 1, 2023)

Amendment No. 2 to Preferred Stock Rights Agreement, dated as of June 26, 2023, by and between Forte Biosciences, Inc. and Computershare Trust Company, N.A., as rights agent (Filed With SEC on August 1, 2023)

Securities Purchase Agreement, dated July 28, 2023, by and among the Company and the Purchasers (Filed With SEC on August 1, 2023)

Registration Rights Agreement, dated July 28, 2023, by and among the Company and the Purchasers (Filed With SEC on August 1, 2023)

Amendment No. 1 to Preferred Stock Rights Agreement, dated as of June 26, 2023, by and between Forte Biosciences, Inc. and Computershare Trust Company, N.A., as rights agent (Filed With SEC on June 26, 2023)

Form of Change in Control and Severance Agreement (Filed With SEC on November 14, 2022)

Offer Letter by and between the Company and Hubert Chen, M.D., dated May 31, 2022 (Filed With SEC on August 15, 2022)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 15, 2022)

Preferred Stock Rights Agreement, dated as of July 12, 2022, by and between Forte Biosciences, Inc. and Computershare Trust Company, N.A., as rights agent (Filed With SEC on July 12, 2022)

At Market Issuance Sales Agreement between the Company and Ladenburg Thalmann & Co. Inc (Filed With SEC on April 1, 2022)

Forte Biosciences, Inc. 2021 Equity Incentive Plan (Filed With SEC on March 31, 2022)

Underwriting Agreement, dated October 29, 2020 (Filed With SEC on October 29, 2020)

At Market Issuance Sales Agreement between the Company and Ladenburg Thalmann & Co. Inc (Filed With SEC on September 4, 2020)

Form of Warrant to Purchase Common Stock of the Registrant issued on June 15, 2020 (Filed With SEC on August 10, 2020)

Amendment No. 2 to License Agreement by and between Forte Subsidiary, Inc. and the U.S. Department of Health and Human Services, as represented by the National Institute of... (Filed With SEC on August 10, 2020)

Agreement for Termination of Lease and Voluntary Surrender of Premises, dated June 10, 2020, by and between Tocagen, Inc. and ARE-SD Region No. 61, LLC (Filed With SEC on June 15, 2020)

Description of Common Stock (Filed With SEC on February 27, 2020)

Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Martin J. Duvall (Filed With SEC on February 27, 2020)

Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Mark Foletta (Filed With SEC on February 27, 2020)

Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Fairooz Kabbinavar M.D (Filed With SEC on February 27, 2020)

First Amendment to Lease Agreement, dated December 16, 2019, by and between the Registrant and AP3-SD1 Campus Point LLC (Filed With SEC on February 27, 2020)

Form of Restricted Stock Unit Grant Notice and Agreement (Filed With SEC on February 27, 2020)

Amended and Restated Executive Employment Agreement, dated February 21, 2020, by and between the Registrant and Douglas Jolly, Ph.D (Filed With SEC on February 27, 2020)

Form of Lock-Up Agreement, dated February 19, 2020, by each of the parties named in each agreement therein (Filed With SEC on February 20, 2020)

Form of Company Support Agreement, dated February 19, 2020, by and between Forte and each of the parties named in each agreement therein (Filed With SEC on February 20, 2020)

Form of Forte Support Agreement, dated February 19, 2020, by and between the Company and each of the parties named in each agreement therein (Filed With SEC on February 20, 2020)

Agreement and Plan of Merger and Reorganization, dated February 19, 2020, by and among the Company, Merger Sub and Forte (Filed With SEC on February 20, 2020)

Consent and Second Amendment to Amended and Restated Loan and Security Agreement, dated October 31, 2019, by and among the Registrant, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 12, 2019)

Executive Employment Agreement, dated February 26, 2019, by and between the Registrant and Fairooz Kabbinavar M.D (Filed With SEC on August 8, 2019)

Executive Employment Agreement, dated April 8, 2019, by and between the Registrant and Harry E. Gruber, M.D (Filed With SEC on August 8, 2019)

Tocagen Inc. 2017 Equity Incentive Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on February 27, 2019)

Underwriting Agreement, dated December 12, 2018, by and among Tocagen Inc. and Citigroup Global Markets Inc. and Leerink Partners LLC, as representatives for the several... (Filed With SEC on December 13, 2018)

Equity Distribution Agreement, dated November 21, 2018, by and between Tocagen Inc. and Citigroup Global Markets Inc (Filed With SEC on November 21, 2018)

Tocagen Inc. 2017 Equity Incentive Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on November 8, 2018)

Warrant to Purchase Stock, dated May 18, 2018, issued to Oxford Finance LLC (Filed With SEC on August 9, 2018)

Warrant to Purchase Stock, dated May 18, 2018, issued to Silicon Valley Bank (Filed With SEC on August 9, 2018)

License Agreement, dated April 18, 2018, by and among the Registrant, Beijing Apollo Venus Biomedical Technology Limited and ApolloBio Corp (Filed With SEC on August 9, 2018)

Amended and Restated Loan and Security Agreement, dated May 18, 2018, by and among the Registrant, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on August 9, 2018)

First Amendment to Amended and Restated Loan and Security Agreement, dated August 3, 2018, by and amount the Registrant, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on August 9, 2018)

Eighteenth Amendment to Lease, dated March 7, 2018, by and between the Registrant and BMR-3030 Bunker Hill Street LLC (Filed With SEC on May 11, 2018)

Amended and Restated Executive Employment Agreement, dated February 12, 2018, by and between the Registrant and Mark Foletta (Filed With SEC on March 9, 2018)

Tocagen Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 9, 2018)

Amended and Restated Executive Employment Agreement, dated February 12, 2018, by and between the Registrant and Martin J. Duvall (Filed With SEC on March 9, 2018)

Executive Employment Agreement, dated February 12, 2018, by and between the Registrant and Asha Das, M.D (Filed With SEC on March 9, 2018)

Executive Employment Agreement, dated February 12, 2018, by and between the Registrant and Douglas Jolly, Ph.D (Filed With SEC on March 9, 2018)

Lease Agreement by and between the Registrant and AP3-SD1 Campus Point LLC, dated December 21, 2017 (Filed With SEC on March 9, 2018)

Seventeenth Amendment to Lease, dated July 25, 2017, by and between the Registrant and BMR-3030 Bunker Hill Street LLC and Eighteenth Amendment to Lease, dated March 7, 2018, by... (Filed With SEC on March 9, 2018)

Tocagen Inc. Annual Incentive Plan (Filed With SEC on August 9, 2017)

Signature(s) Guaranteed: Medallion Guarantee Stamp (Filed With SEC on April 3, 2017)

TOCAGEN INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 31, 2017 APPROVED BY THE STOCKHOLDERS:MARCH 31, 2017 IPO DATE: (Filed With SEC on April 3, 2017)

TOCAGEN INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 31, 2017 APPROVED BY THE STOCKHOLDERS:MARCH 31, 2017 (Filed With SEC on April 3, 2017)

TOCAGEN INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on April 3, 2017)

INDEMNITY AGREEMENT (Filed With SEC on March 9, 2017)

TOCAGEN INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APPROVED BY THE STOCKHOLDERS: (Filed With SEC on March 9, 2017)

WARRANT TO PURCHASE STOCK (Filed With SEC on March 9, 2017)

WARRANT TO PURCHASESTOCK (Filed With SEC on March 9, 2017)

VoicesAgainst Brain Cancer Research and Development Grant Agreement for Tocagen Inc. (Filed With SEC on March 9, 2017)

TOCAGEN INC. WARRANT TOPURCHASE COMMON STOCK (Filed With SEC on March 9, 2017)

TOCAGEN INC. (a Delawarecorporation) [] Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 9, 2017)

TOCAGEN INC. 2009 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD: MARCH 23, 2009 APPROVED BY THE STOCKHOLDERS: MARCH 23, 2009 AMENDED BY THE BOARD: FEBRUARY 16, 2012 APPROVED BY THE... (Filed With SEC on March 9, 2017)

TOCAGEN INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APPROVED BY THE STOCKHOLDERS: IPODATE: (Filed With SEC on March 9, 2017)

TOCAGEN INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on March 9, 2017)

TOCAGEN INC. EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on March 9, 2017)

LOAN AND SECURITY AGREEMENT (Filed With SEC on March 9, 2017)

LEASE by and between BMR-3030 BUNKER HILL STREET LLC, a Delaware limited liability company and TOCAGEN INC., a Delaware corporation LEASE (Filed With SEC on March 9, 2017)

LICENSEAGREEMENT GENE DELIVERY SYSTEM AND METHODS OF USE USC FILE 2862 and HYBRID VECTORS FORGENE THERAPYUSC FILE 2831 (Filed With SEC on March 9, 2017)

FIRST AMENDMENT TO LABORATORY SERVICES AND LICENSE AGREEMENT (TOCAGEN AND SIEMENS) (Filed With SEC on March 9, 2017)

LABORATORY SERVICES AND LICENSE AGREEMENT (TOCAGEN AND SIEMENS) (Filed With SEC on March 9, 2017)

TOCAGEN INC. Appendix A Dr. Asha Das (Filed With SEC on March 9, 2017)

Category

Industry

Companies

Contracts

Tocagen Inc Contracts & Agreements